The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
AACR 2023 | Is immunotherapy less effective in patients with PTEN loss in NSCLC?
Francisco Exposito, PhD, Yale University, New Haven, CT, comments on his research on the role of PTEN loss in the efficacy of PD-1 inhibitors in patients with non-small cell lung cancer (NSCLC). Whilst the current models are preclinical, analysis of lung cancer biopsies confirmed previous findings, and mouse models will further elucidate mechanisms of resistance. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
